NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT06205290 2024-04-02A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 3 Withdrawn
NCT01306643 2018-11-19Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaGilead SciencesPhase 1/2 Completed18 enrolled 8 charts
NCT00710528 2012-08-31Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesGilead SciencesPhase 1 Completed192 enrolled